Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.CytRx names new CFO
Mr Caloz joined CytRx in October 2007 and has served as the company’s chief accounting officer. Prior to joining CytRx, he served as CFO of publicly traded Occulogix
Mr Caloz joined CytRx in October 2007 and has served as the company’s chief accounting officer. Prior to joining CytRx, he served as CFO of publicly traded Occulogix
For instance, should events warrant, Dor will be eligible to submit a new drug application (NDA) for DOR201 on a rolling basis, permitting the FDA to review sections
Results from the studies in hemorrhoidectomy and in total knee arthroplasty are expected to provide the primary clinical data, in addition to extensive existing preclinical and clinical data,
Emergent will pursue full repayment of the $10 million loan, which is secured by substantially all of Protein Sciences’s assets, and settlement of the outstanding litigation against Protein
Labcoat has developed a novel technology for coating drug-eluting stents that uses precisely metered droplets of a biodegradable polymer and drug formulation to create a thin (
Proceeds from the financing will be used to further develop Anacor’s product pipeline based on its boron chemistry platform. The investments from GlaxoSmithKline (GSK) and Schering fulfill each
The transaction represents the final prepaid product-based payment due under the terms of its Hylenex licensing agreement, which provides Baxter with exclusive distribution rights. The payment has been
Mr Colangelo joins Promedior after a nearly 15-year pharmaceutical industry career at Eli Lilly and Company and most recently as executive vice president of corporate development and operations
Mr Silva will assume responsibility for overseeing the US, Canadian and Australian specialty pharmaceuticals operations. Prior to joining Valeant, Mr Silva held various leadership positions with Novartis. His
Under the terms of the agreement, StockerYale will supply optical assemblies to Boston Scientific for various medical applications. Financial terms of the agreement were not disclosed. The signing